triplex DNA (H-DNA)

07/01/2011 - "Therefore, it can be concluded that DNA triplex-based therapeutic approaches hold promise in the treatment of malignancies associated with MET overexpression."
01/28/2023 - "Triplex DNA structure has potential therapeutic application in inhibiting the expression of genes involved in cancer and other diseases. "
05/20/2020 - "We report that the pH-sensitive triplex DNA exhibited outstanding sensitivity and size tunability in triggering the disassembly of AuNP clusters into smaller sizes among the tumor acidic environment, leading to better permeability both in vitro and in vivo. "
01/01/2019 - "Triplex DNA Nanoswitch for pH-Sensitive Release of Multiple Cancer Drugs."
01/01/2018 - "Here, we report that H-DNA-forming sequences are enriched at translocation breakpoints in human cancer genomes, further implicating them in cancer etiology. "

11/19/2021 - "The present study determined the prevalence of EqPV-H in the sera of clinically healthy horses in South Korea to identify the potential factors for infection and examine the genetic diversity of EqPV-H DNA sequences through comparison with foreign strains. "
07/01/2023 - "The occurrence of EqPV-H infection was determined by quantitative PCR for EqPV-H DNA in serum samples. "
10/01/2004 - "The positive SENV-H DNA was significantly associated with HCV genotype 1b than non-1b infection (69.0% versus 43.4%; P = 0.011). "
02/01/2007 - "There was no difference in the positive rates of SENV-D and SENV-H DNA among adolescents with or without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or history of hospitalization, surgery or blood transfusion. "
01/01/2017 - "Immuno-protection assay showed that zebrafish administrated with A.h DNA or designed CpG-ODNs had a significantly enhanced defence against A.h and Vibrio alginolyticus infections, which was also eliminated by the neutralization of hepcidin. "

10/01/2022 - "However, only a subgroup of BTCs with microsatellite-instability high (MSI-H)/DNA mismatch repair-deficient (dMMR) or tumor mutational burden-high (TMB-H) benefit from monotherapy of ICIs, and limited activity was observed in the second or subsequent settings. "
01/01/2021 - "Unfortunately, currently available immunotherapeutics only displayed significant antitumoral activity - in terms of progression free survival (PFS) and objective response rate (ORR) - in microsatellite instability-high (MSI-H)/DNA mismatch repair deficient (dMMR) CRCs. "
11/01/2019 - "Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair-deficient (dMMR) tumors. "
01/01/2022 - "In phase 2, patients with melanoma, non-small-cell lung cancer (NSCLC), and microsatellite instability-high (MSI-H)/DNA mismatch repair-deficient colorectal cancer (CRC) received cetrelimab 240 mg Q2W. "
01/01/2020 - "The only patients who are currently considered for treatment with ICI are those with tumors that are either microsatellite instability-high (MSI-H), DNA mismatch repair deficient (dMMR), or in those with esophageal, GEJ, or gastric adenocarcinomas that have at least one-percent expression of PD-L1 after failing at least two lines of systemic therapy based on early results from the KEYNOTE-059 trial released in 2017, or second-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) with combined positive score (CPS) of 10 or greater based on the combined results from KEYNOTE-180 and KEYNOTE-181 in 2019. "

01/01/2020 - "The only patients who are currently considered for treatment with ICI are those with tumors that are either microsatellite instability-high (MSI-H), DNA mismatch repair deficient (dMMR), or in those with esophageal, GEJ, or gastric adenocarcinomas that have at least one-percent expression of PD-L1 after failing at least two lines of systemic therapy based on early results from the KEYNOTE-059 trial released in 2017, or second-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) with combined positive score (CPS) of 10 or greater based on the combined results from KEYNOTE-180 and KEYNOTE-181 in 2019. "

01/01/2020 - "The only patients who are currently considered for treatment with ICI are those with tumors that are either microsatellite instability-high (MSI-H), DNA mismatch repair deficient (dMMR), or in those with esophageal, GEJ, or gastric adenocarcinomas that have at least one-percent expression of PD-L1 after failing at least two lines of systemic therapy based on early results from the KEYNOTE-059 trial released in 2017, or second-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) with combined positive score (CPS) of 10 or greater based on the combined results from KEYNOTE-180 and KEYNOTE-181 in 2019. "